The role of glial cells in multiple sclerosis disease progression

In this Review, the authors discuss the involvement of astrocytes and microglia in the pathophysiology of progressive multiple sclerosis and consider current and future therapeutic approaches that directly target glial cells. Despite the development of highly effective treatments for relapsing-remitting multiple sclerosis (MS), limited progress has been made in addressing primary progressive or secondary progressive MS, both of which lead to loss of oligodendrocytes and neurons and axons, and to irreversible accumulation of disability. Neuroinflammation is central to all forms of MS. The current effective therapies for relapsing-remitting MS target the peripheral immune system; these treatments, however, have repeatedly failed in progressive MS. Greater understanding of inflammation driven by CNS-resident cells - including astrocytes and microglia - is, therefore, required to identify novel potential therapeutic opportunities. Advances in imaging, biomarker analysis and genomics suggest that microglia and astrocytes have central roles in the progressive disease process. In this Review, we provide an overview of the involvement of astrocytes and microglia at major sites of pathology in progressive MS. We discuss current and future therapeutic approaches to directly target glial cells, either to inhibit pathogenic functions or to restore homeostatic functions lost during the course of the disease. We also discuss how bidirectional communication between astrocytes and microglia needs to be considered, as therapeutic targeting of one is likely to alter the functions of the other.

Automated summary

This Review discusses the involvement of astrocytes and microglia in the pathophysiology of progressive multiple sclerosis and considers current and future therapeutic approaches targeting glial cells. Greater understanding of the roles of these cells is needed to identify novel therapeutic opportunities for progressive MS.